State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Clin Infect Dis. 2012 May;54 Suppl 4:S320-3. doi: 10.1093/cid/cir1016.
In 2003, antiretroviral therapy became available free of charge in China's public health sector. During 2008 and 2009, 10 surveys to classify transmitted human immunodeficiency virus drug resistance (HIVDR) were conducted in 7 regions in 5 provinces (autonomous regions and municipalities) according to World Health Organization guidance. In 2008, transmitted HIVDR was classified as low (<5%) to nucleoside reverse-transcriptase inhibitors, nonnucleoside reverse-transcriptase inhibitors, and protease inhibitors in 6 surveys performed in 6 regions. In 2009, 3 of 4 surveys showed low rates of transmitted HIVDR to all drug classes, and 1 survey showed moderate (5%-15%) rates of transmitted protease inhibitor resistance. In China, routine surveillance of transmitted HIVDR should continue and be expanded to other regions of the country.
2003 年，中国公共卫生领域开始免费提供抗逆转录病毒疗法。2008 年和 2009 年，根据世界卫生组织的指导，在中国 5 个省（自治区、直辖市）的 7 个地区进行了 10 次针对传播的人类免疫缺陷病毒耐药性（HIVDR）分类调查。2008 年，在 6 个地区进行的 6 次调查中，传播的 HIVDR 被归类为核苷逆转录酶抑制剂、非核苷逆转录酶抑制剂和蛋白酶抑制剂的低（<5%）水平。2009 年，4 次调查中的 3 次显示所有药物类别传播的 HIVDR 率较低，1 次调查显示蛋白酶抑制剂耐药率为中度（5%-15%）。在中国，应继续对传播的 HIVDR 进行常规监测，并扩大到全国其他地区。
